نتایج جستجو برای: dual antiplatelet therapy

تعداد نتایج: 804061  

2014
Ju-Hyun Lee Sang-Heon Park In Ae Song

Discontinuation of dual antiplatelet therapy within 12 months after drug-eluting stent (DES) implantation increases the possibility of stent thrombosis. We now report the case of a 66-year-old man who suffered a cardiac arrest due to stent thrombosis after an elective laparoscopic anterior resection. Ten month ago, he underwent DES implantation and then had been taking dual antiplatelet therapy...

2013
Jonas Oldgren Lars Wallentin John H. Alexander Stefan James Birgitta Jönelid Gabriel Steg Johan Sundström

BACKGROUND Oral anticoagulation in addition to antiplatelet treatment after an acute coronary syndrome might reduce ischaemic events but increase bleeding risk. We performed a meta-analysis to evaluate the efficacy and safety of adding direct thrombin or factor-Xa inhibition by any of the novel oral anticoagulants (apixaban, dabigatran, darexaban, rivaroxaban, and ximelagatran) to single (aspir...

2012
Hamid Reza Poorhosseini Seyed Kianoosh Hosseini Tahereh Davarpasand Masoumeh Lotfi Tokaldany Mojtaba Salarifar Seyed Ebrahim Kassaian Mohammad Alidoosti Younes Nozari Ebrahim Nematipour Ali Mohammad Haji Zeinali Hasan Aghajani Ali Reza Amirzadegan

BACKGROUND Impact of 12 months' versus 24 months' use of dual antiplatelet therapy on the prevalence of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI) with the drug-eluting stent (DES) is not clear. As a result, duration of dual antiplatelet therapy is still under debate among interventionists. METHODS From March 2007 until August 2008, all consecutive patien...

Journal: :Circulation. Cardiovascular interventions 2012
Fadi Al-Rashid Thomas F M Konorza Björn Plicht Daniel Wendt Matthias Thielmann Heinz Jakob Raimund Erbel Philipp Kahlert

Transcatheter aortic valve implantation (TAVI) is considered a transformational novel technology for the treatment of severe symptomatic aortic valve stenosis. It has been rapidly adopted in the clinical arena and meanwhile evolved to the standard of care for inoperable and an acceptable alternative for high-risk but operable patients.1,2 In analogy to surgical bioprosthetic aortic valve replac...

Journal: :European heart journal 2007
Thomas H Wang Deepak L Bhatt Keith A A Fox Steven R Steinhubl Danielle M Brennan Werner Hacke Koon-Hou Mak Thomas A Pearson William E Boden P Gabriel Steg Marcus D Flather Gilles Montalescot Eric J Topol

AIMS To examine the unanticipated, excess mortality observed in patients randomized to clopidogrel and aspirin vs. aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population. METHODS AND RESULTS Of 15 603 patients enrolled, 3284 were initia...

Journal: :Circulation 2013
Steven K Feske

M y grandmother used to say, " If a little'll do a little good, a lot'll do a lotta good. " Unfortunately, it is not that simple with antiplatelet agents. Many relevant facts are well established. In identifiable subgroups of patients who present with transient ischemic attacks (TIAs) or minor strokes, the risk of a subsequent stroke is high. Most of this risk is incurred during the first few d...

Journal: :Journal of the American College of Cardiology 2017

Journal: :Journal of the American College of Cardiology 2017

Journal: :European Heart Journal Supplements 2007

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید